MedDataX Logo

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

NCT ID: NCT00736099

Last Updated: 2014-06-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

2122 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the current study is to investigate the safety and tolerability of BI 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment.

The treatment modalities are determined by the treatment in the blinded trial in which every patient was included previously as BI 1356 in monotherapy (patients in 1218.16 trial), BI 1356 in combination with pioglitazone (patients in 1218.15 trial), BI 1356 added to metformin background (patients in 1218.17 trial) or BI 1356 added to a background therapy of metformin in combination with a sulphonylurea (patients in 1218.18 study)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

NCT00716092

Diabetes Mellitus, Type 2
COMPLETED PHASE2

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

NCT00819091

Diabetes Mellitus, Type 2
COMPLETED PHASE3

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

NCT01289990

Diabetes Mellitus, Type 2
COMPLETED PHASE3

Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control

NCT01214239

Diabetes Mellitus, Type 2
COMPLETED PHASE3

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

NCT00996658

Diabetes Mellitus, Type 2
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

linagliptin 5 mg

open label

Group Type EXPERIMENTAL

linagliptine 5 mg

Intervention Type DRUG

safety and efficacy of linagliptine 5 mg open label

linagliptin 5 mg and pioglitazone 30 mg

open label

Group Type EXPERIMENTAL

linagliptine 5 mg and pioglitazone 30 mg

Intervention Type DRUG

efficacy and safety of the combination linagliptine and pioglitazone

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

linagliptine 5 mg

safety and efficacy of linagliptine 5 mg open label

Intervention Type DRUG

linagliptine 5 mg and pioglitazone 30 mg

efficacy and safety of the combination linagliptine and pioglitazone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed and dated written informed consent in accordance with the GCP and local legislation.
2. Patients completing the entire treatment period as a double blind trial whether or not they have been treated with rescue medication.

Exclusion Criteria

1. Patients who meet one or more of the withdrawal criteria of the treatment period of the previous trial.
2. Pre-menopausal women (last menstruation =\< 1 year prior to signing informed consent) who:

* are nursing or pregnant,
* or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, true sexual abstinence (when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence \[e.g. calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of birth control) and vasectomised partners. No exception will be made.
3. Alcohol abuse within the 3 months prior to informed consent that would interfere with trial participation.
4. Drug abuse which, in the opinion of the investigator, would interfere with trial participation.
5. Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the trial medication.
Minimum Eligible Age

18 Years

Maximum Eligible Age

82 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1218.40.10003 Boehringer Ingelheim Investigational Site

Chula Vista, California, United States

Site Status

1218.40.10014 Boehringer Ingelheim Investigational Site

Spring Valley, California, United States

Site Status

1218.40.10001 Boehringer Ingelheim Investigational Site

Walnut Creek, California, United States

Site Status

1218.40.10021 Boehringer Ingelheim Investigational Site

Northglenn, Colorado, United States

Site Status

1218.40.10010 Boehringer Ingelheim Investigational Site

Hollywood, Florida, United States

Site Status

1218.40.10011 Boehringer Ingelheim Investigational Site

Miami, Florida, United States

Site Status

1218.40.10016 Boehringer Ingelheim Investigational Site

Eugene, Oregon, United States

Site Status

1218.40.10002 Boehringer Ingelheim Investigational Site

Greer, South Carolina, United States

Site Status

1218.40.10004 Boehringer Ingelheim Investigational Site

Simpsonville, South Carolina, United States

Site Status

1218.40.10005 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

1218.40.10018 Boehringer Ingelheim Investigational Site

Houston, Texas, United States

Site Status

1218.40.10007 Boehringer Ingelheim Investigational Site

San Antonio, Texas, United States

Site Status

1218.40.10009 Boehringer Ingelheim Investigational Site

Federal Way, Washington, United States

Site Status

1218.40.54002 Boehringer Ingelheim Investigational Site

Capital Federal, , Argentina

Site Status

1218.40.54010 Boehringer Ingelheim Investigational Site

Capital Federal, , Argentina

Site Status

1218.40.54011 Boehringer Ingelheim Investigational Site

Mendoza, , Argentina

Site Status

1218.40.54015 Boehringer Ingelheim Investigational Site

Parque Velez Sarfield, , Argentina

Site Status

1218.40.43001 Boehringer Ingelheim Investigational Site

Graz, , Austria

Site Status

1218.40.43005 Boehringer Ingelheim Investigational Site

Vienna, , Austria

Site Status

1218.40.32005 Boehringer Ingelheim Investigational Site

Bruges, , Belgium

Site Status

1218.40.32007 Boehringer Ingelheim Investigational Site

Brussels, , Belgium

Site Status

1218.40.32006 Boehringer Ingelheim Investigational Site

Edegem, , Belgium

Site Status

1218.40.32004 Boehringer Ingelheim Investigational Site

Genk, , Belgium

Site Status

1218.40.32003 Boehringer Ingelheim Investigational Site

Ghent, , Belgium

Site Status

1218.40.32002 Boehringer Ingelheim Investigational Site

Huy, , Belgium

Site Status

1218.40.32001 Boehringer Ingelheim Investigational Site

Liège, , Belgium

Site Status

1218.40.01005 Boehringer Ingelheim Investigational Site

Calgary, Alberta, Canada

Site Status

1218.40.01010 Boehringer Ingelheim Investigational Site

Calgary, Alberta, Canada

Site Status

1218.40.01003 Boehringer Ingelheim Investigational Site

Vancouver, British Columbia, Canada

Site Status

1218.40.01011 Boehringer Ingelheim Investigational Site

Vancouver, British Columbia, Canada

Site Status

1218.40.01006 Boehringer Ingelheim Investigational Site

Etobicoke, Ontario, Canada

Site Status

1218.40.01009 Boehringer Ingelheim Investigational Site

Hamilton, Ontario, Canada

Site Status

1218.40.01002 Boehringer Ingelheim Investigational Site

London, Ontario, Canada

Site Status

1218.40.01012 Boehringer Ingelheim Investigational Site

Oakville, Ontario, Canada

Site Status

1218.40.01008 Boehringer Ingelheim Investigational Site

Sarnia, Ontario, Canada

Site Status

1218.40.20005 Boehringer Ingelheim Investigational Site

Strathroy, Ontario, Canada

Site Status

1218.40.01001 Boehringer Ingelheim Investigational Site

Toronto, Ontario, Canada

Site Status

1218.40.01004 Boehringer Ingelheim Investigational Site

Montague, Prince Edward Island, Canada

Site Status

1218.40.01007 Boehringer Ingelheim Investigational Site

Saskatoon, Saskatchewan, Canada

Site Status

1218.40.86001 Boehringer Ingelheim Investigational Site

Beijing, , China

Site Status

1218.40.86002 Boehringer Ingelheim Investigational Site

Beijing, , China

Site Status

1218.40.86004 Boehringer Ingelheim Investigational Site

Beijing, , China

Site Status

1218.40.86013 Boehringer Ingelheim Investigational Site

Chengdu, , China

Site Status

1218.40.86009 Boehringer Ingelheim Investigational Site

Dalian, , China

Site Status

1218.40.86011 Boehringer Ingelheim Investigational Site

Guangzhou, , China

Site Status

1218.40.86014 Boehringer Ingelheim Investigational Site

Haerbin, , China

Site Status

1218.40.86008 Boehringer Ingelheim Investigational Site

Qingdao, , China

Site Status

1218.40.86015 Boehringer Ingelheim Investigational Site

Shanghai, , China

Site Status

1218.40.86010 Boehringer Ingelheim Investigational Site

Shenyang, , China

Site Status

1218.40.86007 Boehringer Ingelheim Investigational Site

Wuhan, , China

Site Status

1218.40.86012 Boehringer Ingelheim Investigational Site

Wuhan, , China

Site Status

1218.40.86006 Boehringer Ingelheim Investigational Site

Xi'an, , China

Site Status

1218.40.38605 Boehringer Ingelheim Investigational Site

Krapinske Toplice, , Croatia

Site Status

1218.40.38604 Boehringer Ingelheim Investigational Site

Slavonski Brod, , Croatia

Site Status

1218.40.42004 Boehringer Ingelheim Investigational Site

Brno, , Czechia

Site Status

1218.40.42007 Boehringer Ingelheim Investigational Site

Brno, , Czechia

Site Status

1218.40.42009 Boehringer Ingelheim Investigational Site

Brno, , Czechia

Site Status

1218.40.42006 Boehringer Ingelheim Investigational Site

Břeclav, , Czechia

Site Status

1218.40.42008 Boehringer Ingelheim Investigational Site

Hodonín, , Czechia

Site Status

1218.40.42003 Boehringer Ingelheim Investigational Site

Olomouc, , Czechia

Site Status

1218.40.35806 Boehringer Ingelheim Investigational Site

Helsinki, , Finland

Site Status

1218.40.35801 Boehringer Ingelheim Investigational Site

Kuopio, , Finland

Site Status

1218.40.35803 Boehringer Ingelheim Investigational Site

Oulu, , Finland

Site Status

1218.40.35805 Boehringer Ingelheim Investigational Site

Seinäjoki, , Finland

Site Status

1218.40.35802 Boehringer Ingelheim Investigational Site

Turku, , Finland

Site Status

1218.40.49028 Boehringer Ingelheim Investigational Site

Bad Mergentheim, , Germany

Site Status

1218.40.49022 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

1218.40.49024 Boehringer Ingelheim Investigational Site

Bosenheim, , Germany

Site Status

1218.40.49020 Boehringer Ingelheim Investigational Site

Dresden, , Germany

Site Status

1218.40.49101 Boehringer Ingelheim Investigational Site

Mainz, , Germany

Site Status

1218.40.49003 Boehringer Ingelheim Investigational Site

Neuwied, , Germany

Site Status

1218.40.49007 Boehringer Ingelheim Investigational Site

Nuremberg, , Germany

Site Status

1218.40.49014 Boehringer Ingelheim Investigational Site

Saarbrücken, , Germany

Site Status

1218.40.30004 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

1218.40.30007 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

1218.40.30013 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

1218.40.30003 Boehringer Ingelheim Investigational Site

Nikaia, , Greece

Site Status

1218.40.30011 Boehringer Ingelheim Investigational Site

Piraeus, , Greece

Site Status

1218.40.30006 Boehringer Ingelheim Investigational Site

Thessaloniki, , Greece

Site Status

1218.40.30016 Boehringer Ingelheim Investigational Site

Thessaloniki, , Greece

Site Status

1218.40.36003 Boehringer Ingelheim Investigational Site

Budapest, , Hungary

Site Status

1218.40.36004 Boehringer Ingelheim Investigational Site

Budapest, , Hungary

Site Status

1218.40.36006 Boehringer Ingelheim Investigational Site

Budapest, , Hungary

Site Status

1218.40.36008 Boehringer Ingelheim Investigational Site

Debrecen, , Hungary

Site Status

1218.40.36005 Boehringer Ingelheim Investigational Site

Győr, , Hungary

Site Status

1218.40.36002 Boehringer Ingelheim Investigational Site

Szombathely, , Hungary

Site Status

1218.40.91010 Boehringer Ingelheim Investigational Site

Andhra Pradesh, , India

Site Status

1218.40.91002 Boehringer Ingelheim Investigational Site

Bangalore, , India

Site Status

1218.40.91005 Boehringer Ingelheim Investigational Site

Bangalore, , India

Site Status

1218.40.91012 Boehringer Ingelheim Investigational Site

Chennai, , India

Site Status

1218.40.91014 Boehringer Ingelheim Investigational Site

Chennai, , India

Site Status

1218.40.91009 Boehringer Ingelheim Investigational Site

Hyderabad, Andra Pradesh, , India

Site Status

1218.40.91006 Boehringer Ingelheim Investigational Site

Jaipur, , India

Site Status

1218.40.91001 Boehringer Ingelheim Investigational Site

Kerala, , India

Site Status

1218.40.91011 Boehringer Ingelheim Investigational Site

Maharashtra, , India

Site Status

1218.40.91008 Boehringer Ingelheim Investigational Site

Mangalore, , India

Site Status

1218.40.91007 Boehringer Ingelheim Investigational Site

Manipal, , India

Site Status

1218.40.91004 Boehringer Ingelheim Investigational Site

Mumbai, , India

Site Status

1218.40.91003 Boehringer Ingelheim Investigational Site

Nashik, , India

Site Status

1218.40.91013 Boehringer Ingelheim Investigational Site

Uttar Pradesh, , India

Site Status

1218.40.97274 Boehringer Ingelheim Investigational Site

Afula, , Israel

Site Status

1218.40.97273 Boehringer Ingelheim Investigational Site

Haifa, , Israel

Site Status

1218.40.97275 Boehringer Ingelheim Investigational Site

Holon, , Israel

Site Status

1218.40.97271 Boehringer Ingelheim Investigational Site

Jerusalem, , Israel

Site Status

1218.40.97272 Boehringer Ingelheim Investigational Site

Nahariya, , Israel

Site Status

1218.40.97276 Boehringer Ingelheim Investigational Site

Safed, , Israel

Site Status

1218.40.97278 Boehringer Ingelheim Investigational Site

Tel Aviv, , Israel

Site Status

1218.40.39008 Boehringer Ingelheim Investigational Site

Genova, , Italy

Site Status

1218.40.39002 Boehringer Ingelheim Investigational Site

Milan, , Italy

Site Status

1218.40.39001 Boehringer Ingelheim Investigational Site

Pisa, , Italy

Site Status

1218.40.39006 Boehringer Ingelheim Investigational Site

Roma, , Italy

Site Status

1218.40.81001 Boehringer Ingelheim Investigational Site

Amagasaki, Hyogo, , Japan

Site Status

1218.40.81005 Boehringer Ingelheim Investigational Site

Koganei, Tokyo, , Japan

Site Status

1218.40.81002 Boehringer Ingelheim Investigational Site

Osaka, Osaka, , Japan

Site Status

1218.40.81004 Boehringer Ingelheim Investigational Site

Shinjyuku-ku,Tokyo, , Japan

Site Status

1218.40.81003 Boehringer Ingelheim Investigational Site

Suita, Osaka,, , Japan

Site Status

1218.40.60007 Boehringer Ingelheim Investigational Site

George Town, , Malaysia

Site Status

1218.40.60003 Boehringer Ingelheim Investigational Site

Kelantan, , Malaysia

Site Status

1218.40.60001 Boehringer Ingelheim Investigational Site

Kuala Lumpur, , Malaysia

Site Status

1218.40.60002 Boehringer Ingelheim Investigational Site

Kuala Lumpur, , Malaysia

Site Status

1218.40.60004 Boehringer Ingelheim Investigational Site

Perak, , Malaysia

Site Status

1218.40.60005 Boehringer Ingelheim Investigational Site

Perak, , Malaysia

Site Status

1218.40.52007 Boehringer Ingelheim Investigational Site

Aguascalientes, Ags., , Mexico

Site Status

1218.40.52010 Boehringer Ingelheim Investigational Site

Col.Americana, Guadalajara, Jalisco, , Mexico

Site Status

1218.40.52008 Boehringer Ingelheim Investigational Site

Colonia Tlalpan, Mexico, , Mexico

Site Status

1218.40.52006 Boehringer Ingelheim Investigational Site

Faccionamiento Lomas de Campestre,AGUASCAL, , Mexico

Site Status

1218.40.52009 Boehringer Ingelheim Investigational Site

León, , Mexico

Site Status

1218.40.52002 Boehringer Ingelheim Investigational Site

México, , Mexico

Site Status

1218.40.52004 Boehringer Ingelheim Investigational Site

México, , Mexico

Site Status

1218.40.52005 Boehringer Ingelheim Investigational Site

México, , Mexico

Site Status

1218.40.52003 Boehringer Ingelheim Investigational Site

Monterrey, , Mexico

Site Status

1218.40.52001 Boehringer Ingelheim Investigational Site

Monterrey N.L., , Mexico

Site Status

1218.40.31006 Boehringer Ingelheim Investigational Site

Deurne, , Netherlands

Site Status

1218.40.31001 Boehringer Ingelheim Investigational Site

Ewijk, , Netherlands

Site Status

1218.40.31010 Boehringer Ingelheim Investigational Site

Losser, , Netherlands

Site Status

1218.40.31008 Boehringer Ingelheim Investigational Site

Roelofarendsveen, , Netherlands

Site Status

1218.40.31002 Boehringer Ingelheim Investigational Site

Wildervank, , Netherlands

Site Status

1218.40.64004 Boehringer Ingelheim Investigational Site

Christchurch, , New Zealand

Site Status

1218.40.64003 Boehringer Ingelheim Investigational Site

Dunedin, , New Zealand

Site Status

1218.40.64002 Boehringer Ingelheim Investigational Site

Otahuhu, , New Zealand

Site Status

1218.40.64001 Boehringer Ingelheim Investigational Site

Tauranga, , New Zealand

Site Status

1218.40.64005 Boehringer Ingelheim Investigational Site

Wellington, , New Zealand

Site Status

1218.40.63003 Boehringer Ingelheim Investigational Site

Greenhills, San Juan, , Philippines

Site Status

1218.40.63005 Boehringer Ingelheim Investigational Site

Manila, , Philippines

Site Status

1218.40.63002 Boehringer Ingelheim Investigational Site

Marikina City, , Philippines

Site Status

1218.40.63001 Boehringer Ingelheim Investigational Site

Pasig, , Philippines

Site Status

1218.40.63004 Boehringer Ingelheim Investigational Site

Quezon City, , Philippines

Site Status

1218.40.48603 Boehringer Ingelheim Investigational Site

Lublin, , Poland

Site Status

1218.40.48601 Boehringer Ingelheim Investigational Site

Warsaw, , Poland

Site Status

1218.40.48604 Boehringer Ingelheim Investigational Site

Zabrze, , Poland

Site Status

1218.40.40504 Boehringer Ingelheim Investigational Site

Alba Iulia, , Romania

Site Status

1218.40.40604 Boehringer Ingelheim Investigational Site

Brasov, , Romania

Site Status

1218.40.40501 Boehringer Ingelheim Investigational Site

Bucharest, , Romania

Site Status

1218.40.40502 Boehringer Ingelheim Investigational Site

Bucharest, , Romania

Site Status

1218.40.40603 Boehringer Ingelheim Investigational Site

Galati, , Romania

Site Status

1218.40.40503 Boehringer Ingelheim Investigational Site

Sibiu, , Romania

Site Status

1218.40.40505 Boehringer Ingelheim Investigational Site

Târgu Mureş, , Romania

Site Status

1218.40.70014 Boehringer Ingelheim Investigational Site

Arkhangelsk, , Russia

Site Status

1218.40.70001 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1218.40.70002 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1218.40.70003 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1218.40.70012 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1218.40.70005 Boehringer Ingelheim Investigational Site

Novosibirsk, , Russia

Site Status

1218.40.70006 Boehringer Ingelheim Investigational Site

Perm, , Russia

Site Status

1218.40.70013 Boehringer Ingelheim Investigational Site

Rostov-on-Don, , Russia

Site Status

1218.40.70015 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

1218.40.70016 Boehringer Ingelheim Investigational Site

Samara, , Russia

Site Status

1218.40.70004 Boehringer Ingelheim Investigational Site

Tomsk, , Russia

Site Status

1218.40.42103 Boehringer Ingelheim Investigational Site

Banská Bystrica, , Slovakia

Site Status

1218.40.42102 Boehringer Ingelheim Investigational Site

Bratislava, , Slovakia

Site Status

1218.40.42104 Boehringer Ingelheim Investigational Site

Bratislava, , Slovakia

Site Status

1218.40.42105 Boehringer Ingelheim Investigational Site

Bratislava, , Slovakia

Site Status

1218.40.42101 Boehringer Ingelheim Investigational Site

Nové Mesto, , Slovakia

Site Status

1218.40.42106 Boehringer Ingelheim Investigational Site

Šamorín, , Slovakia

Site Status

1218.40.82002 Boehringer Ingelheim Investigational Site

Busan, , South Korea

Site Status

1218.40.82011 Boehringer Ingelheim Investigational Site

Daegu, , South Korea

Site Status

1218.40.82008 Boehringer Ingelheim Investigational Site

Incheon, , South Korea

Site Status

1218.40.82010 Boehringer Ingelheim Investigational Site

Jeonju, , South Korea

Site Status

1218.40.82004 Boehringer Ingelheim Investigational Site

Pusan, , South Korea

Site Status

1218.40.82001 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

1218.40.82005 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

1218.40.82006 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

1218.40.82007 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

1218.40.82009 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

1218.40.82003 Boehringer Ingelheim Investigational Site

Suwon, , South Korea

Site Status

1218.40.34002 Boehringer Ingelheim Investigational Site

Badalona, , Spain

Site Status

1218.40.34011 Boehringer Ingelheim Investigational Site

Badia Del Vallés, , Spain

Site Status

1218.40.34012 Boehringer Ingelheim Investigational Site

Borges Del Camp, , Spain

Site Status

1218.40.34013 Boehringer Ingelheim Investigational Site

Centelles, , Spain

Site Status

1218.40.34007 Boehringer Ingelheim Investigational Site

Granada, , Spain

Site Status

1218.40.34008 Boehringer Ingelheim Investigational Site

L'Hospitalet de Llobregat (Barcelona), , Spain

Site Status

1218.40.34009 Boehringer Ingelheim Investigational Site

L'Hospitalet de Llobregat (Barcelona), , Spain

Site Status

1218.40.34004 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1218.40.34006 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1218.40.34010 Boehringer Ingelheim Investigational Site

Sant Adrià Del Besós (Barcelona), , Spain

Site Status

1218.40.34005 Boehringer Ingelheim Investigational Site

Seville, , Spain

Site Status

1218.40.34014 Boehringer Ingelheim Investigational Site

Vic (Barcelona), , Spain

Site Status

1218.40.46013 Boehringer Ingelheim Investigational Site

Härnösand, , Sweden

Site Status

1218.40.46001 Boehringer Ingelheim Investigational Site

Malmo, , Sweden

Site Status

1218.40.46012 Boehringer Ingelheim Investigational Site

Uddevalla, , Sweden

Site Status

1218.40.46004 Boehringer Ingelheim Investigational Site

Uppsala, , Sweden

Site Status

1218.40.88605 Boehringer Ingelheim Investigational Site

Changhua, , Taiwan

Site Status

1218.40.88604 Boehringer Ingelheim Investigational Site

Taichung, , Taiwan

Site Status

1218.40.88606 Boehringer Ingelheim Investigational Site

Tainan City, , Taiwan

Site Status

1218.40.88601 Boehringer Ingelheim Investigational Site

Taipei, , Taiwan

Site Status

1218.40.88602 Boehringer Ingelheim Investigational Site

Taipei, , Taiwan

Site Status

1218.40.88603 Boehringer Ingelheim Investigational Site

Taipei, , Taiwan

Site Status

1218.40.88607 Boehringer Ingelheim Investigational Site

Taipei, , Taiwan

Site Status

1218.40.88608 Boehringer Ingelheim Investigational Site

Taoyuan District, , Taiwan

Site Status

1218.40.66001 Boehringer Ingelheim Investigational Site

Bangkok, , Thailand

Site Status

1218.40.66002 Boehringer Ingelheim Investigational Site

Khon Kaen, , Thailand

Site Status

1218.40.38011 Boehringer Ingelheim Investigational Site

Dnipro, , Ukraine

Site Status

1218.40.38002 Boehringer Ingelheim Investigational Site

Kharkiv, , Ukraine

Site Status

1218.40.38004 Boehringer Ingelheim Investigational Site

Kharkiv, , Ukraine

Site Status

1218.40.38010 Boehringer Ingelheim Investigational Site

Kharkiv, , Ukraine

Site Status

1218.40.38001 Boehringer Ingelheim Investigational Site

Kiev, , Ukraine

Site Status

1218.40.38005 Boehringer Ingelheim Investigational Site

Kiev, , Ukraine

Site Status

1218.40.38008 Boehringer Ingelheim Investigational Site

Kiev, , Ukraine

Site Status

1218.40.38009 Boehringer Ingelheim Investigational Site

Kiev, , Ukraine

Site Status

1218.40.38012 Boehringer Ingelheim Investigational Site

Kiev, , Ukraine

Site Status

1218.40.38003 Boehringer Ingelheim Investigational Site

Lviv, , Ukraine

Site Status

1218.40.38006 Boehringer Ingelheim Investigational Site

Vinnitsa, , Ukraine

Site Status

1218.40.38007 Boehringer Ingelheim Investigational Site

Zaporizhzhya, , Ukraine

Site Status

1218.40.44005 Boehringer Ingelheim Investigational Site

Ashford, , United Kingdom

Site Status

1218.40.44004 Boehringer Ingelheim Investigational Site

Baillieston, Glasgow, , United Kingdom

Site Status

1218.40.44001 Boehringer Ingelheim Investigational Site

Bath, , United Kingdom

Site Status

1218.40.44003 Boehringer Ingelheim Investigational Site

Burbage, , United Kingdom

Site Status

1218.40.44010 Boehringer Ingelheim Investigational Site

Bury Saint Edmonds, , United Kingdom

Site Status

1218.40.44009 Boehringer Ingelheim Investigational Site

Cardiff, , United Kingdom

Site Status

1218.40.44002 Boehringer Ingelheim Investigational Site

Penarth, , United Kingdom

Site Status

1218.40.44006 Boehringer Ingelheim Investigational Site

Reading, , United Kingdom

Site Status

1218.40.44007 Boehringer Ingelheim Investigational Site

Waterloo, Liverpool, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Austria Belgium Canada China Croatia Czechia Finland Germany Greece Hungary India Israel Italy Japan Malaysia Mexico Netherlands New Zealand Philippines Poland Romania Russia Slovakia South Korea Spain Sweden Taiwan Thailand Ukraine United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008-000750-13

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1218.40

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
NCT01177813 COMPLETED PHASE3
Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
NCT01084005 COMPLETED PHASE3
A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes
NCT03115099 COMPLETED PHASE1
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
NCT01087502 COMPLETED PHASE3
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes
NCT00954447 COMPLETED PHASE3
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
NCT01734785 COMPLETED PHASE3
Linagliptin Add-on to Insulin Background Therapy
NCT02897349 COMPLETED PHASE3
A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
NCT01119846 COMPLETED PHASE2
Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin
NCT00753896 COMPLETED PHASE3
Pharmacokinetics/Pharmacodynamics of Albiglutide
NCT01357889 COMPLETED PHASE2
Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes
NCT01824264 WITHDRAWN PHASE2
Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
NCT00881530 COMPLETED PHASE2
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
NCT00749190 COMPLETED PHASE2
Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes
NCT01345734 COMPLETED
Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes
NCT00359879 COMPLETED PHASE3
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus
NCT02111096 TERMINATED PHASE2
Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)
NCT02318693 COMPLETED PHASE4
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
NCT01098539 COMPLETED PHASE3
A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes
NCT01408888 COMPLETED PHASE1
Add Glucokinase Activator to Target A1c
NCT02405260 COMPLETED PHASE2
Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin
NCT00757588 COMPLETED PHASE3
Initial Combination With Pioglitazone Study (0431-064)
NCT00397631 COMPLETED PHASE3
A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics
NCT01441232 COMPLETED PHASE1
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes
NCT01035879 COMPLETED PHASE2
A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus
NCT01707147 COMPLETED